| MCW Ca Bioenergetics Biosaf | Office L | Jse Only 7-158 | | | | | |
|---|----------|--|-----|----|--|--|--|
| Cell Type(s) | Ce | ells adherent/primary culture? | Yes | No | | | |
| Human | | Name of Cell Type(s): | | | | | |
| Non-Human Primate | | | | | | | |
| Mouse | | | | | | | |
| Rat | | Is this cell type tested for human pathogens? | Yes | No | | | |
| Cell Type(s) | | Clinical Sample? | Yes | No | | | |
| Human Blood Products | | Name of Cell Type(s): | | | | | |
| Purified Cell Extracts | | | | | | | |
| Microorgainism | | | | | | | |
| Protein/Peptide/Liposome | | to the could be a stand for the second state of the second | | | | | |
| Other | | Is this cell type tested for human pathogens? | Yes | No | | | |
| rDNA/Transformed with Viral Vector? Yes No | | | | | | | |
| If "Yes": Adenovirus AAV MicroRNA Other Describe method and generation of rDNA/viral vector as well as any special precautions that needs to be taken: | | | | | | | |

| Infected with Pathogen or Infectious Agent? Yes No | | | | | | | | |
|---|--|--|--|--|--|--|--|--|
| If "Yes" list pathogen(s) and/or infectious agent(s) as well as any special precautions that needs to be taken: | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| If "Yes" list chemicals as well as any special precautions that need to be taken. Designate where and who will be handling | | | | | | | | |
| these chemicals. Safety Data Sheets (SDS) for each chemical used need to be provided. Please check to see if your agent is a particularly bazardous substance, bttps://infoscone.mcw.edu/EHS/Biological-Safety/Select-Agente-Toying | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| The MCW Cancer Center Pedex & Ricenergetics Shared Resource (CCRSR) provides expertise in collular metabolism | | | | | | | | |
| analysis. A diverse range of samples from multiple users are analyzed, including notentially infectious materials. This | | | | | | | | |
| form needs to be accurately filled out so we know how to safely process your sample. We use the Biosafety in | | | | | | | | |
| Microbiological & Biomedical Laboratories (BMBL) as a guide to perform the risk assessment on your sample. Your | | | | | | | | |
| cooperation in providing the above information is greatly appreciated so that we are able to safely process your | | | | | | | | |
| sample in a timely manner. Once approved, samples in closed containers transported in secondary containment may | | | | | | | | |
| be submitted for analysis. | | | | | | | | |

| Administrative Information | | | | | | | |
|--|--------------------------|----------------------|-------------|--|--|--|--|
| Prin | cipal Investigator (PI): | Other Lab Contact(s) | Phone/Email | | | | |
| Name | | | | | | | |
| Phone | | | | | | | |
| Fax | | | | | | | |
| Email | | | | | | | |
| Institution | | | | | | | |
| Department | | | | | | | |
| | | | | | | | |
| Project Information | | | | | | | |
| Date | | | | | | | |
| Title | | | | | | | |
| IBC Protocol # Approval Date | | | | | | | |
| IBC Title | | | | | | | |
| Approval Letter | | | | | | | |
| | | | | | | | |
| Please provide a description of the goals of your proposed experiment. | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| Please indicate any sample processing steps that will be performed in the Center other than routine instrument | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

Principle Investigator Disclosure Information

Principle Investigators are responsible for accurate disclosure of sample information. Approval is required **PRIOR** to sample submission to the center to allow for the necessary safety precautions. Biosafety Disclosure Forms will be evaluated promptly upon receipt to prevent delay of experimentation. Additional documentation may be requested prior to sample approval. **Please contact Monika Zielonka**, at 414-955-4059 in room MFRC 2013 with any questions regarding this form.

I have carefully read the Biosafety Disclosure Form and certify the information provided to be correct.

Signature of Principle Investigator

Date